EU green-lights Opdivo for melanoma; U.K. plans Bexsero vaccination drive;

> Bristol-Myers Squibb ($BMY) won European approval for its PD-1 immunotherapy Opdivo as a treatment for advanced melanoma, for first-line use as well as for patients who've been treated previously. Release

> The U.K. plans the world's first publicly funded vaccination drive against meningitis B, using Bexsero, the shot developed by Novartis ($NVS) and sold to GlaxoSmithKline ($GSK) in a multibillion-dollar asset swap earlier this year. Report

> A case series published in Diabetes Care advised that SGLT2 diabetes drugs only be used "with great caution" in patients with Type 1 diabetes. Report

> Pfizer's ($PFE) Centrum brand team rolled out a survey in Canada showing Canadians consume as many daily servings of caffeine as fruits and vegetables. Report

> A Texas judge decided that FDA labeling rules didn't pre-empt state regulations on off-label promotions in a case accusing a drugmaker of illegally marketing generic Cordarone for unapproved use. Report

And Finally...  Federal officials charged 11 people in a conspiracy to market millions of bottles of counterfeit 5-hour Energy drinks in the U.S. Report

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.